Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension. The data, which was presented recently at 20th Scientific Meeting of the European Society of Hypertension (ESH) in Oslo, and was discussed today at a briefing in Stockholm, also demonstrate the consistently higher BP control/response rates achieved compared to treatment with telmisartan or amlodipine treatment alone.
“Compelling results for the telmisartan and amlodipine combination have resulted in the recent positive opinion adopted by the European Committee for Medicinal Products for Human Use (CHMP).”
"These latest data confirm that combination therapies provide a valuable treatment option for patients, especially those with severe hypertension. The results demonstrate that the combination of telmisartan and amlodipine provides reliable reduction in blood pressure and offers a more favourable safety profile than the respective individual therapies - an important consideration for improving adherence which is often a barrier to effective blood pressure control," said Professor Michael Böhm, Director and Chief of Department of Internal Medicine and Cardiology at the University of Saarland in Germany. "Compelling results for the telmisartan and amlodipine combination have resulted in the recent positive opinion adopted by the European Committee for Medicinal Products for Human Use (CHMP)."
Telmisartan and amlodipine are the two longest acting components in their class providing reliable 24 hour reduction in blood pressure. Telmisartan is also the only ARB with an indication of cardiovascular protection in patients at risk of serious cardiovascular events.